17. Multiple system atrophy Clinical trials / Disease details
Clinical trials : 118 / Drugs : 163 - (DrugBank : 49) / Drug target genes : 61 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01287221 (ClinicalTrials.gov) | March 2011 | 28/1/2011 | Study of Rifampicin in Multiple System Atrophy | Double-Blind, Placebo-Controlled Study of Rifampicin in Multiple System Atrophy | Multiple System Atrophy | Drug: Rifampicin;Drug: placebo | Phillip Low | National Institute of Neurological Disorders and Stroke (NINDS);Vanderbilt University;Rare Disease Research Network Autonomic Consortium | Terminated | 30 Years | 80 Years | All | 100 | Phase 3 | United States |